Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
NVO News
In early February 2026, Novo Nordisk filed a patent infringement lawsuit against Hims & Hers over its compounded semaglutide weight-loss products, following an...
Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape. Ozempic has been one of Novo Nordisk's (NVO +1.31%) main growth drivers for sever...
Growth, value, or both? Healthcare industry stocks are traditionally good hedges against technology and other growth stocks, because they tend to perform well...
Analyst ratings
53%
of 34 ratingsMore NVO News
Novo Nordisk (NYSE:NVO) has taken legal action against Hims & Hers over compounded versions of its Wegovy pill that do not have individual FDA approval. The FD...
Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper...
Novo Nordisk (NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S (NVO) has completed a phase 3 study titled “Efficacy and Safety of Ora...
Berenberg lowered the firm’s price target on Novo Nordisk (NVO) to DKK 360 from DKK 415 and keeps a Buy rating on the shares. Published first on TheFly – the u...
Novo Nordisk A/S (NYSE:NVO) plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to strengthen its position against ri...
Options trades to play for a short squeeze in Hims & Hers as the pain piles up Hims & Hers has been clobbered over the past week as the telehealth company step...
Novo Nordisk (NVO) announced an update on their ongoing clinical study. Novo Nordisk (NVO) has completed a phase 2 trial titled “Effects of NNC0194-0499 Alone...